Amneal closes acquisition of Kashiv BioSciences to build biosimilars platform

Amneal Pharmaceuticals, Inc. completed its acquisition of Kashiv BioSciences, LLC on August 10, 2026, purchasing 100% of the issued and outstanding membership interests of Kashiv from its equityholders.¹ The deal follows a Membership Interest Purchase Agreement dated April 21, 2026.¹

Under the terms, Amneal LLC paid the sellers $375,000,000 in cash, subject to adjustments for cash, funding of operations between signing and closing, indebtedness, transaction expenses and working capital fluctuations, and Amneal issued 28,942,108 shares of Class A common stock to the sellers, subject to adjustment for fractional shares.¹ The final share count issued at closing was 28,942,098, as adjusted downward for fractional shares.¹

The sellers could receive additional payments: up to $350,000,000 in contingent payments tied to regulatory milestones for up to six designated Kashiv product candidates.¹ Separately, over a 12-year period following closing, sellers are eligible for royalty payments equal to 25% of the amount by which annual gross profits for certain products exceed specified hurdles.¹

To help fund the purchase, Amneal LLC entered into a fourth amendment to its term loan credit agreement with JPMorgan Chase Bank as administrative agent, under which Bank of America made an incremental term loan of $350,000,000 to Amneal LLC, the proceeds of which were used as a portion of the consideration for the acquisition.¹

Amneal also amended its stockholders agreement with the Amneal Group Representative to clarify how shares issued to Amneal Group members in the deal would be counted for purposes of the stockholders agreement, since certain sellers are affiliates of the Amneal Group.¹

The company said the transaction combines Kashiv's biologics R&D and manufacturing with Amneal's commercial infrastructure. Amneal intends to file Kashiv's financial statements and pro forma financial information by amendment no later than 71 calendar days after the report's required filing date.¹